טוען...
Different infusion durations for preventing platinum‐induced hearing loss in children with cancer
BACKGROUND: Platinum‐based therapy, including cisplatin, carboplatin or oxaliplatin, or a combination of these, is used to treat a variety of paediatric malignancies. Unfortunately, one of the most important adverse effects is the occurrence of hearing loss or ototoxicity. In an effort to prevent th...
שמור ב:
| הוצא לאור ב: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley & Sons, Ltd
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6516894/ https://ncbi.nlm.nih.gov/pubmed/29975402 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010885.pub4 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|